ZLNA ZELLUNA ASA

Zelluna ASA: Disclosure of large shareholding

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the "Private Placement"), divided on a first tranche of 3,729,774 new shares and a second tranche of 1,770,226 new shares ("Tranche 2"), and the allocation of 315,639 new shares in a retail offering via the PrimaryBid Platform. 

Radforsk Investeringsstiftelse ("Radforsk") holds 2,469,693 shares in the Company, currently representing 10.08% of the total number of shares and votes in the Company.

The issuance of the 1,770,226 new shares in Tranche 2 of the Private Placement was approved by the extraordinary general meeting of the Company held on 25 November 2025. Following registration of the share capital increase pertaining to the issuance of the new shares in Tranche 2 with the Norwegian Register of Business Enterprises, the shareholding of Radforsk will, as a result of the dilutive effect of such share capital increase, cross below the 10% threshold pursuant to section 4-2 of the Norwegian Securities Trading Act. The shareholding of Radforsk will at such time continue to be 2,469,693 shares, which after registration of the share capital increase will be equal to 9.40% of the shares and votes in the Company.

This disclosure is made pursuant to Section 4-2 of the Norwegian Securities Trading Act.



EN
27/11/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE

Zelluna Reaches Major Milestone and Submits Clinical Trial Application...

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours On track for initial clinical data in mid-2026Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf cell therapies for cancer, today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulat...

 PRESS RELEASE

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk stu...

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Storbritannia for første studie på mennesker av ZI-MA4-1 (ZIMA-101), verdens første MAGE-A4-rettede TCR-NK celleterapi for solide kreftformer. Forventer første kliniske data fra midten av 2026Markerer et viktig skritt mot skalerbare, tilgjengelige "off-the-shelf" celleterapier for solide kreftformer Oslo, Norge, 17. desember 2025 – Zelluna (OSE: ZLNA), et bioteknologiselskap som utvikler allogene "off-the-shelf" celleterapier mot kreft, kunngjorde i dag at selskapet har innlevert søknad om oppstart av klinisk studi...

 PRESS RELEASE

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World'...

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today announced the publication of preclinical data for its lead candidate, ZI-MA4-1, in the peer-reviewed journal Immunotherapy Advances*. The data support the company's plan to start clinical trials in 2026. The paper describes ZI-MA4-1, a novel cell therapy that combines tw...

 PRESS RELEASE

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell The...

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important step in developing scalable and accessible ‘off-the-shelf’ cell therapy for patients with solid tumours Oslo, Norway, 12 December, 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today announced the successful manufacture and Q...

 PRESS RELEASE

Zelluna ASA: Cancellation of subsequent repair offering

Zelluna ASA: Cancellation of subsequent repair offering NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. Oslo, 9 December, 2025: Reference is made to the stock exchange announcement published by Zelluna ASA ("Zelluna" or the "Company") on 3 November 2025 regarding the private placement (the "Private Placement"), and the intention to carry out a subsequent repair offering (the "Subsequent Offering"), depending, inter alia, on...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch